# A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

> **NCT06649448** · NA · NOT_YET_RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 200 (estimated)

## Conditions studied

- Solid Tumor Cancer
- Chemotherapy Induced Neutropenia
- G-CSF

## Interventions

- **DRUG:** Efbemalenograstim alfa Injection
- **DRUG:** carboplatin/cisplatin-etoposide
- **DRUG:** Carboplatin plus Paclitaxel
- **DRUG:** Cisplatin/pemetrexed or Carboplatin/pemetrexed
- **DRUG:** TP regimen

## Key facts

- **NCT ID:** NCT06649448
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649448, "A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06649448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*